BACKGROUND: We previously identified aryl hydrocarbon receptor (AHR) as a novel regulator of megakaryocytic differentiation and polyploidization and reported that AHR-null mice have approximately 15% fewer platelets than do wild-type mice, yet they exhibit a dramatic, unexplained bleeding phenotype. OBJECTIVES: The current work tests our hypothesis that AHR-null platelets are functionally deficient, contributing to the previously reported (yet unexplained) bleeding phenotype present in AHR-null mice. METHODS: AHR-null bone marrow was ex vivo differentiated with thrombopoietin with or without AHR ligands or AHR inhibitors and analyzed for degree of megakaryopoiesis and polyploidization. Platelet function of AHR-null mice was assessed with aggregation and spreading assays. Platelet signaling was examined using Western analysis and Rac activity assays. RESULTS: AHR ligands differentiate murine bone marrow-derived progenitors into polyploid megakaryocytes in the absence of thrombopoietin, and AHR inhibitors block thrombopoietin-induced megakaryocytic differentiation. Despite their responsiveness toward thrombin, AHR-null platelets demonstrate decreased aggregation and spreading in response to collagen compared with wild-type platelets. AHR-null platelets bind fibrinogen after stimulation with thrombin or AYPGKF and aggregate in response to AYPGKF and adenosine diphosphate. Mechanistically, AHR absence led to down-regulation of Vav1 and Vav3, altered phospholipase Cγ2 phosphorylation, decreased Rac1 activation, and reduced platelet activation in response to collagen. CONCLUSIONS: These results are consistent with a role for AHR in platelet function, especially as it relates to platelet aggregation and spreading in response to collagen. Our work suggests AHR is a critical component of the physiologic response that platelets undergo in response to collagen and may provide novel treatment options for patients with bleeding disorders.
BACKGROUND: We previously identified aryl hydrocarbon receptor (AHR) as a novel regulator of megakaryocytic differentiation and polyploidization and reported that AHR-null mice have approximately 15% fewer platelets than do wild-type mice, yet they exhibit a dramatic, unexplained bleeding phenotype. OBJECTIVES: The current work tests our hypothesis that AHR-null platelets are functionally deficient, contributing to the previously reported (yet unexplained) bleeding phenotype present in AHR-null mice. METHODS:AHR-null bone marrow was ex vivo differentiated with thrombopoietin with or without AHR ligands or AHR inhibitors and analyzed for degree of megakaryopoiesis and polyploidization. Platelet function of AHR-null mice was assessed with aggregation and spreading assays. Platelet signaling was examined using Western analysis and Rac activity assays. RESULTS:AHR ligands differentiate murine bone marrow-derived progenitors into polyploid megakaryocytes in the absence of thrombopoietin, and AHR inhibitors block thrombopoietin-induced megakaryocytic differentiation. Despite their responsiveness toward thrombin, AHR-null platelets demonstrate decreased aggregation and spreading in response to collagen compared with wild-type platelets. AHR-null platelets bind fibrinogen after stimulation with thrombin or AYPGKF and aggregate in response to AYPGKF and adenosine diphosphate. Mechanistically, AHR absence led to down-regulation of Vav1 and Vav3, altered phospholipase Cγ2 phosphorylation, decreased Rac1 activation, and reduced platelet activation in response to collagen. CONCLUSIONS: These results are consistent with a role for AHR in platelet function, especially as it relates to platelet aggregation and spreading in response to collagen. Our work suggests AHR is a critical component of the physiologic response that platelets undergo in response to collagen and may provide novel treatment options for patients with bleeding disorders.
Authors: Rolf P Kreutz; Jeffrey A Breall; Yvonne Kreutz; Janelle Owens; Deshun Lu; Islam Bolad; Elisabeth von der Lohe; Anjan Sinha; David A Flockhart Journal: Thromb Res Date: 2012-03-28 Impact factor: 3.944
Authors: Vincent Sauzeau; José M Carvajal-González; Adelaida S Riolobos; María A Sevilla; Mauricio Menacho-Márquez; Angel C Román; Antonio Abad; María J Montero; Pedro Fernández-Salguero; Xosé R Bustelo Journal: J Biol Chem Date: 2010-11-29 Impact factor: 5.157
Authors: Pani A Apostolidis; Stephan Lindsey; William M Miller; Eleftherios T Papoutsakis Journal: Physiol Genomics Date: 2012-05-01 Impact factor: 3.107
Authors: Jose M Carvajal-Gonzalez; Sonia Mulero-Navarro; Angel Carlos Roman; Vincent Sauzeau; Jaime M Merino; Xose R Bustelo; Pedro M Fernandez-Salguero Journal: Mol Biol Cell Date: 2009-01-21 Impact factor: 4.138
Authors: Catherine Strassel; Nathalie Brouard; Lea Mallo; Nicolas Receveur; Pierre Mangin; Anita Eckly; Ivan Bieche; Karin Tarte; Christian Gachet; François Lanza Journal: Blood Date: 2016-03-10 Impact factor: 22.113
Authors: Stephan Lindsey; Joseph H Piatt; Peter Worthington; Cem Sönmez; Sameer Satheye; Joel P Schneider; Darrin J Pochan; Sigrid A Langhans Journal: Biomacromolecules Date: 2015-08-17 Impact factor: 6.988
Authors: Rance Nault; Kelly A Fader; Anna K Kopec; Jack R Harkema; Timothy R Zacharewski; James P Luyendyk Journal: Toxicol Sci Date: 2016-09-09 Impact factor: 4.849
Authors: Malgorzata Karbowska; Tomasz W Kaminski; Beata Znorko; Tomasz Domaniewski; Tomasz Misztal; Tomasz Rusak; Anna Pryczynicz; Katarzyna Guzinska-Ustymowicz; Krystyna Pawlak; Dariusz Pawlak Journal: Front Physiol Date: 2018-11-28 Impact factor: 4.566
Authors: Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps Journal: Front Immunol Date: 2015-02-13 Impact factor: 7.561